SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AVIGEN(avgn)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (155)11/1/1999 1:03:00 PM
From: JMarcus  Read Replies (1) of 228
 
The current human trials involved Hemophilia A and Factor IX. The press release concerns animal trials involving Hemophilia B and Factor VIII. Apparently the gene responsible for producing Factor VIII is very large and this posed an obstacle to using the AAV vector to deliver it. The good news from the press release is that Avigen succeeded in splitting the Factor VIII gene and delivering it in "two sequences via two separate AAV vectors." This bodes well for expanding the future use of the AAV vector, because it demonstrates a workaround for the size limitation.

I plan to attend the shareholders meeting on Nov. 12th, but don't really expect any news on the pending Phase I clinical trials until the ASH meeting December 3rd.

Marc
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News